...
首页> 外文期刊>Alimentary pharmacology & therapeutics. >Systematic review: Probiotics in the management of lower gastrointestinal symptoms in clinical practice - An evidence-based international guide
【24h】

Systematic review: Probiotics in the management of lower gastrointestinal symptoms in clinical practice - An evidence-based international guide

机译:系统评价:益生菌在临床实践中控制下消化道症状-循证国际指南

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Evidence suggests that the gut microbiota play an important role in gastrointestinal problems. Aim: To give clinicians a practical reference guide on the role of specified probiotics in managing particular lower gastrointestinal symptoms/problems by means of a systematic review-based consensus. Methods: Systematic literature searching identified randomised, placebo-controlled trials in adults; evidence for each symptom/problem was graded and statements developed (consensus process; 10-member panel). As results cannot be generalised between different probiotics, individual probiotics were identified for each statement. Results: Thirty seven studies were included; mostly on irritable bowel syndrome [IBS; 19 studies; treatment responder rates: 18-80% (specific probiotics), 5-50% (placebo)] or antibiotic-associated diarrhoea (AAD; 10 studies). Statements with 100% agreement and 'high' evidence levels indicated that: (i) specific probiotics help reduce overall symptom burden and abdominal pain in some IBS patients; (ii) in patients receiving antibiotics/Helicobacter pylori eradication therapy, specified probiotics are helpful as adjuvants to prevent/reduce the duration/intensity of AAD; (iii) probiotics have favourable safety in patients in primary care. Items with 70-100% agreement and 'moderate' evidence were: (i) specific probiotics help relieve overall symptom burden in some patients with diarrhoea-predominant IBS, and reduce bloating/distension and improve bowel movement frequency/consistency in some IBS patients and (ii) with some probiotics, improved symptoms have led to improvement in quality of life. Conclusions: Specified probiotics can provide benefit in IBS and antibiotic-associated diarrhoea; relatively few studies in other indications suggested benefits warranting further research. This study provides practical guidance on which probiotic to select for a specific problem.
机译:背景:证据表明肠道菌群在胃肠道疾病中起重要作用。目的:通过基于系统评价的共识,为临床医生提供关于特定益生菌在管理特定的下消化道症状/问题中的作用的实用参考指南。方法:系统性文献检索确定了成人随机,安慰剂对照试验;对每种症状/问题的证据进行分级,并提出陈述(共识过程; 10人小组)。由于不同的益生菌之间的结果不能一概而论,因此针对每种陈述确定了单独的益生菌。结果:共纳入37项研究。主要是肠易激综合症[IBS; 19项研究;治疗有效率:18-80%(特定的益生菌),5-50%(安慰剂)]或抗生素相关性腹泻(AAD; 10个研究)。具有100%一致性和“高”证据水平的陈述表明:(i)特定的益生菌有助于减轻某些IBS患者的总体症状负担和腹痛; (ii)在接受抗生素/幽门螺杆菌根除治疗的患者中,特定的益生菌有助于预防/减少AAD的持续时间/强度。 (iii)益生菌在初级保健患者中具有良好的安全性。具有70-100%一致性和“中度”证据的项目是:(i)特定的益生菌有助于减轻某些腹泻型IBS患者的总体症状负担,并减少某些IBS患者的腹胀/腹胀并改善排便频率/一致性,以及(ii)对于某些益生菌,症状的改善导致生活质量的改善。结论:特定的益生菌可以改善IBS和抗生素相关的腹泻。其他适应症的研究相对较少,提示其益处值得进一步研究。这项研究为选择特定问题的益生菌提供了实用指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号